Tender for the Supply of "Epclusa" Tablets DDΧΔΠΔ SPYY 148/2025 (OAY)

This tender concerns the procurement of "Epclusa" tablets, a medication used in the treatment of Hepatitis C. The tender is issued under reference number DDΧΔΠΔ SPYY 148/2025 by the Organisation of Healthcare Services (OAY). The primary objective is to secure a supply of this specific pharmaceutical product to meet the needs of the healthcare system. "Epclusa" is a direct-acting antiviral (DAA) medication that has been instrumental in achieving high cure rates for Hepatitis C infection. The tender likely specifies the required quantities, quality standards, packaging, delivery timelines, and any specific regulatory compliance requirements for the supplied "Epclusa" tablets. Bidders are expected to be pharmaceutical suppliers or manufacturers capable of meeting these specifications. Further details regarding eligibility criteria, submission procedures, evaluation methods, and contract duration will be outlined in the full tender documentation. This procurement is crucial for ensuring continued access to effective Hepatitis C treatment for patients within the jurisdiction served by OAY, contributing to the public health objectives of disease eradication and patient well-being. The tender emphasizes the importance of reliable and timely supply of essential medicines.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals and Infectious Diseases. Located in CY, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.